PancPRO: Risk assessment for individuals with a family history of pancreatic cancer

Wenyi Wang, Sining Chen, Kieran A. Brune, Ralph H Hruban, Giovanni Parmigiani, Alison Klein

Research output: Contribution to journalArticle

Abstract

Purpose: The rapid fatality of pancreatic cancer is, in large part, the result of an advanced stage of diagnosis for the majority of patients. Identification of individuals at high risk of developing pancreatic cancer is a first step towards the early detection of this disease. Individuals who may harbor a major pancreatic cancer susceptibility gene are one such high-risk group. The goal of this study was to develop and validate PancPRO, a Mendelian model for pancreatic cancer risk prediction in individuals with familial pancreatic cancer, to identify high-risk individuals. Methods: PancPRO was built by extending the Bayesian modeling framework developed for BRCAPRO, trained using published data, and validated using independent prospective data on 961 families enrolled onto the National Familial Pancreas Tumor Registry, including 26 individuals who developed incident pancreatic cancer during follow-up. Results: We developed a risk prediction model, PancPRO, and free software for the estimation of pancreatic cancer susceptibility gene carrier probabilities and absolute pancreatic cancer risk. Model validation demonstrated an observed to predicted pancreatic cancer ratio of 0.83 (95% CI, 0.52 to 1.20) and high discriminatory ability, with an area under the receiver operating characteristic curve of 0.75 (95% CI, 0.68 to 0.81) for PancPRO. Conclusion: PancPRO is the first risk prediction model for pancreatic cancer. When we validated our model using the largest registry of familial pancreatic cancer, our model provided accurate risk assessment. Our findings highlight the importance of detailed family history for clinical cancer risk assessment and demonstrate that accurate genetic risk assessment is possible even when the causative genes are not known.

Original languageEnglish (US)
Pages (from-to)1417-1422
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number11
DOIs
StatePublished - Apr 10 2007

Fingerprint

Pancreatic Neoplasms
Neoplasm Genes
Registries
Aptitude
ROC Curve
Early Diagnosis
Pancreas
Neoplasms
Software

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

PancPRO : Risk assessment for individuals with a family history of pancreatic cancer. / Wang, Wenyi; Chen, Sining; Brune, Kieran A.; Hruban, Ralph H; Parmigiani, Giovanni; Klein, Alison.

In: Journal of Clinical Oncology, Vol. 25, No. 11, 10.04.2007, p. 1417-1422.

Research output: Contribution to journalArticle

Wang, Wenyi ; Chen, Sining ; Brune, Kieran A. ; Hruban, Ralph H ; Parmigiani, Giovanni ; Klein, Alison. / PancPRO : Risk assessment for individuals with a family history of pancreatic cancer. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 11. pp. 1417-1422.
@article{32dcf5efa16941f49a8e2993640d2855,
title = "PancPRO: Risk assessment for individuals with a family history of pancreatic cancer",
abstract = "Purpose: The rapid fatality of pancreatic cancer is, in large part, the result of an advanced stage of diagnosis for the majority of patients. Identification of individuals at high risk of developing pancreatic cancer is a first step towards the early detection of this disease. Individuals who may harbor a major pancreatic cancer susceptibility gene are one such high-risk group. The goal of this study was to develop and validate PancPRO, a Mendelian model for pancreatic cancer risk prediction in individuals with familial pancreatic cancer, to identify high-risk individuals. Methods: PancPRO was built by extending the Bayesian modeling framework developed for BRCAPRO, trained using published data, and validated using independent prospective data on 961 families enrolled onto the National Familial Pancreas Tumor Registry, including 26 individuals who developed incident pancreatic cancer during follow-up. Results: We developed a risk prediction model, PancPRO, and free software for the estimation of pancreatic cancer susceptibility gene carrier probabilities and absolute pancreatic cancer risk. Model validation demonstrated an observed to predicted pancreatic cancer ratio of 0.83 (95{\%} CI, 0.52 to 1.20) and high discriminatory ability, with an area under the receiver operating characteristic curve of 0.75 (95{\%} CI, 0.68 to 0.81) for PancPRO. Conclusion: PancPRO is the first risk prediction model for pancreatic cancer. When we validated our model using the largest registry of familial pancreatic cancer, our model provided accurate risk assessment. Our findings highlight the importance of detailed family history for clinical cancer risk assessment and demonstrate that accurate genetic risk assessment is possible even when the causative genes are not known.",
author = "Wenyi Wang and Sining Chen and Brune, {Kieran A.} and Hruban, {Ralph H} and Giovanni Parmigiani and Alison Klein",
year = "2007",
month = "4",
day = "10",
doi = "10.1200/JCO.2006.09.2452",
language = "English (US)",
volume = "25",
pages = "1417--1422",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - PancPRO

T2 - Risk assessment for individuals with a family history of pancreatic cancer

AU - Wang, Wenyi

AU - Chen, Sining

AU - Brune, Kieran A.

AU - Hruban, Ralph H

AU - Parmigiani, Giovanni

AU - Klein, Alison

PY - 2007/4/10

Y1 - 2007/4/10

N2 - Purpose: The rapid fatality of pancreatic cancer is, in large part, the result of an advanced stage of diagnosis for the majority of patients. Identification of individuals at high risk of developing pancreatic cancer is a first step towards the early detection of this disease. Individuals who may harbor a major pancreatic cancer susceptibility gene are one such high-risk group. The goal of this study was to develop and validate PancPRO, a Mendelian model for pancreatic cancer risk prediction in individuals with familial pancreatic cancer, to identify high-risk individuals. Methods: PancPRO was built by extending the Bayesian modeling framework developed for BRCAPRO, trained using published data, and validated using independent prospective data on 961 families enrolled onto the National Familial Pancreas Tumor Registry, including 26 individuals who developed incident pancreatic cancer during follow-up. Results: We developed a risk prediction model, PancPRO, and free software for the estimation of pancreatic cancer susceptibility gene carrier probabilities and absolute pancreatic cancer risk. Model validation demonstrated an observed to predicted pancreatic cancer ratio of 0.83 (95% CI, 0.52 to 1.20) and high discriminatory ability, with an area under the receiver operating characteristic curve of 0.75 (95% CI, 0.68 to 0.81) for PancPRO. Conclusion: PancPRO is the first risk prediction model for pancreatic cancer. When we validated our model using the largest registry of familial pancreatic cancer, our model provided accurate risk assessment. Our findings highlight the importance of detailed family history for clinical cancer risk assessment and demonstrate that accurate genetic risk assessment is possible even when the causative genes are not known.

AB - Purpose: The rapid fatality of pancreatic cancer is, in large part, the result of an advanced stage of diagnosis for the majority of patients. Identification of individuals at high risk of developing pancreatic cancer is a first step towards the early detection of this disease. Individuals who may harbor a major pancreatic cancer susceptibility gene are one such high-risk group. The goal of this study was to develop and validate PancPRO, a Mendelian model for pancreatic cancer risk prediction in individuals with familial pancreatic cancer, to identify high-risk individuals. Methods: PancPRO was built by extending the Bayesian modeling framework developed for BRCAPRO, trained using published data, and validated using independent prospective data on 961 families enrolled onto the National Familial Pancreas Tumor Registry, including 26 individuals who developed incident pancreatic cancer during follow-up. Results: We developed a risk prediction model, PancPRO, and free software for the estimation of pancreatic cancer susceptibility gene carrier probabilities and absolute pancreatic cancer risk. Model validation demonstrated an observed to predicted pancreatic cancer ratio of 0.83 (95% CI, 0.52 to 1.20) and high discriminatory ability, with an area under the receiver operating characteristic curve of 0.75 (95% CI, 0.68 to 0.81) for PancPRO. Conclusion: PancPRO is the first risk prediction model for pancreatic cancer. When we validated our model using the largest registry of familial pancreatic cancer, our model provided accurate risk assessment. Our findings highlight the importance of detailed family history for clinical cancer risk assessment and demonstrate that accurate genetic risk assessment is possible even when the causative genes are not known.

UR - http://www.scopus.com/inward/record.url?scp=34248210562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248210562&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.09.2452

DO - 10.1200/JCO.2006.09.2452

M3 - Article

C2 - 17416862

AN - SCOPUS:34248210562

VL - 25

SP - 1417

EP - 1422

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -